Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02210195 · ClinicalTrials.gov registry record · Phase 2
Pharmacological Treatment of Comorbid Alcohol and Marijuana Withdrawal and Dependence
A Phase 2 study, sponsored by The Scripps Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT02210195 is a Phase 2 study that has completed, run by The Scripps Research Institute. The registered enrollment target is 20 participants.
The verdict
NCT02210195, a Phase 2 study, has completed, sponsored by The Scripps Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
The primary aim of the supplemental study is to provide POC testing of aprepitant as a treatment for comorbid alcohol and cannabis dependence. The data analysis plan specified in the parent grant will likewise be applied to the supplemental project to test for effects of aprepitant vs placebo on measures of alcohol and cannabis use and protracted withdrawal. The primary hypothesis is that subjects treated with aprepitant will have significantly less alcohol and marijuana use than subjects treated with placebo.
Interventions
- DRUG Placebo
- DRUG aprepitant
- BEHAVIORAL Manual-guided behavioral counseling
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2014-09-04 |
| Est. Completion | 2016-12-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02210195
The ClinicalTrials.gov registry entry for NCT02210195 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Scripps Research Institute, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02210195 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02210195 about?
NCT02210195 is a clinical study titled "Pharmacological Treatment of Comorbid Alcohol and Marijuana Withdrawal and Dependence". The primary aim of the supplemental study is to provide POC testing of aprepitant as a treatment for comorbid alcohol and cannabis dependence. The data analysis plan specified in the parent grant will likewise be applied to the supplemental project to test for effects of aprepitant vs placebo on mea...
What is the current status of trial NCT02210195?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2014-09-04. Estimated completion is 2016-12-19.
What interventions are being tested in trial NCT02210195?
The interventions under investigation include: Placebo (DRUG), aprepitant (DRUG), Manual-guided behavioral counseling (BEHAVIORAL).
Who is sponsoring clinical trial NCT02210195?
This trial is sponsored by The Scripps Research Institute, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.